The proton nuclear magnetic resonance ( 1 H NMR) spectra were determined on a Bruker AVANCE II (300 MHz or 400 MHz) spectrometer. Chemical shifts for 1 H NMR were reported in parts per million (ppm) downfield from tetramethylsilane (δ) as the internal standard in deuterated solvent and coupling constants (J) are in Hertz ( CERI, Japan) with a temperature of 40 °C and a flow rate of 1.2 or 1.5 mL/min or an Waters X-Bridge C18 (4.6 × 50 mm I.D., 3.5 µm) with a temperature of 40 °C and a flow rate of 2.0 mL/min. Mobile Phase: Condition 1: Mobile phases A and B under an acidic condition were 0.05% TFA in water and 0.05% TFA in MeCN, respectively. The ratio of mobile phase B was increased linearly from 5% to 90% over 0.9 min, 90% over the next 1.1 min, or the ratio of mobile phase B was increased linearly from 5% to 100% over 1.6 min, 100% over the next 1.4 min, or the ratio of mobile phase B was increased linearly from 5% to 100% over 3.0 min, 100% over the next 1.0 min. mmol/L ammonium acetate and MeCN (1:9, v/v), respectively. The ratio of mobile phase B was increased linearly from 5% to 95% over 3 min, 95% over the next 1 min.
2-((6-(4-(2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)acetyl)piperazin-1-yl)-2-methylpyr imidin-4-yl)amino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide (11).
A mixture of 10 (456 mg, 0.69 mmol) and triphenylphosphine (363 mg, 1.38 mmol) in THF (6 mL)-water (0.2 mL) was stirred at room temperature overnight. After the mixture was concentrated in vacuo, the residue was purified by column chromatography (NH silica gel, eluted with 0-40% MeOH in EtOAc) to give the title compound 11 (466 mg, quant.) as a pale yellow solid. 1 (1) (12) (230 mg, 0.43 mmol), HATU (193 mg, 0.51 mmol) , and DIPEA (0.13 mL, 0.75 mmol) was stirred at 0 °C for 10 min. The mixture was diluted with EtOAc, washed with 5% NaHCO 3 aq. and brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by column chromatography (silica gel, eluted with 0-20%MeOH in EtOAc) to give the title compound 13 (335 mg, 81%) as a colorless solid. 1 H NMR (300 MHz, CD 3 OD) δ 6 ,6,9-trioxa-12,15-diazanonadecan-1-oyl)piperazin-1
-yl)-2-methylpyrimidin-4-yl)am ino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide (14, SNIPER(ABL)-020).
A mixture of 13 (335 mg, 0.29 mmol) and 2M dimethylamine in MeOH (6 mL, 12 mmol) was stirred at room temperature overnight. After the mixture was concentrated in vacuo, the residue was purified by column chromatography (NH silica gel, eluted with 0-20% MeOH in EtOAc) to give the title compound 14 (233 mg, 86%) as a colorless (HPLC).
tert-Butyl

((S)-1-(((S)-2-((S)-2-(((S)-1-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)-thiazol-
2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)-1,13-dioxo-15,15-diphenyl-3,6,
9-trioxa-12-azapentadecan-14-yl)carbamoyl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoeth yl)amino)-1-oxopropan-2-yl)(methyl)carbamate (16).
A mixture of 11 (229 mg, 0.36 
mmol), (S)-2-((S)-1-((S)-2-((S)-2-((tert-butoxycarbonyl)
(methyl)amino)propanamido)-2-cyclohexylacetyl)pyrrolidine-2-carboxamido)-3,3-diph enylpropanoic acid (2) (15) (288 mg, 0.43 mmol), DIPEA (0.13 mL, 0.75 mmol), and HATU (193 mg, 0.51 mmol) in DMF (6 mL) was stirred at 0 °C for 10 min. The mixture was diluted with EtOAc, washed with 5% NaHCO 3 aq. and brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by column chromatography (silica gel, eluted with 0-30% MeOH in EtOAc) to give the title compound 16 (373 mg, 81%) as a colorless solid. 
2-((6-(4-((S)-3-Benzhydryl-1-((S)-1-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propa namido)acetyl)pyrrolidin-2-yl)-1,4-dioxo-8,11,14-trioxa-2,5-diazahexadecan-16-oyl )piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-N-(2-chloro-6-methylphenyl)thiaz ole-5-carboxamide (17, SNIPER(ABL)-019).
for 10 min. The mixture was diluted with toluene (5 mL) and concentrated in vacuo.
The residue was dissolved in EtOAc-THF(ca 3:1), washed with sat. NaHCO 3 aq. and brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by column chromatography (NH silica gel, eluted with 0-20% MeOH in EtOAc) to give the title compound 17 (317 mg, 92%) as a colorless solid. 1 
tert-Butyl
((2S)-1-(((1S)-1-cyclohexyl-2-oxo-2-((2S)-2-(4-(3-(2-((tetrahydro-2H-pyran-2-yl)-ox y)ethoxy)benzoyl)thiazol-2-yl)pyrrolidin-1-yl)ethyl)amino)-1-oxopropan-2-yl)(met hyl)carbamate (20).
A mixture of tert-butyl
((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(4-(3-hydroxybenzoyl)thiazol-2-yl)-
pyrrolidin-1-yl)-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate (2) (18) (600 mg, 1.00 mmol), 2-(2-bromoethoxy)tetrahydro-2H-pyran (19) (0.46 mL, 3.04 mmol), and K 2 CO 3 (415 mg, 3.00 mmol) in dry DMF (3 mL) was stirred at 50 °C for 3 h. After cooling, the mixture was diluted with EtOAc, washed with water and brine, dried over 
tert-Butyl
((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(4-(3-(2-hydroxyethoxy)benzoyl)thiazol-2-yl)-pyrrolidin-1-yl)-2-oxoethyl)amino)-1-oxopropan-2-yl)(methyl)carbamate (21).
A mixture of 20 (602 mg, 0.83 mmol) and PPTS (24 mg, 0.10 mmol) in MeOH (4 mL) was stirred at room temperature overnight. The mixture was neutralized with sat. 
tert-Butyl
2-(2-(3-(2-((S)-1-((S)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-
2-cyclohexylacetyl)pyrrolidin-2-yl)thiazole-4-carbonyl)phenoxy)ethoxy)acetate (23).
To a mixture of 21 (206 mg, 0.32 mmol) in dry DMF (3 mL) was added 60% NaH in oil (20 mg, 0.50 mmol) at 0 °C. After being stirred at 0 °C for 10 min, tert-butyl 2-bromoacetate (22) (93 µL, 0.64 mmol) was added to the reaction mixture. The mixture was stirred at 0 °C for 2 h. The mixture was poured into 5% NaHCO 3 aq. and extracted with EtOAc. The organic layer was washed with 5% NaHCO 3 aq. and brine, dried over Na 2 SO 4 , and concentrated in vacuo. A mixture of 31a (235 mg, 0.21 mmol) in TFA (3 mL) was stirred at room temperature for 10 min. After the mixture was concentrated in vacuo, the residue was dissolved in 
tert-Butyl
((S)-1-(((S)-2-((S)-2-(4-(3-(2-(2-(4-(6-((5-
(
N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-(2-(3-(2-((S)-1-((S)-2-cyclohexyl-2-((S
)
Methyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate (29b).
To a mixture of 28b (667 mg, 3.74 mmol) in pyridine (16 mL) was added p-TsCl (2.85 g, 15.0 mmol) at 0 °C. The mixture was stirred at room temperature for 4 h. After the mixture was concentrated in vacuo, the residue was dissolved in EtOAc, washed with 1M HCl aq., sat. NaHCO 3 aq., and brine, dried over Na 2 SO 4 , and concentrated in vacuo.
The residue was purified by column chromatography (silica gel, eluted with 50-100% A mixture of 31b (189 mg, 0.16 mmol) in TFA (4.5 mL) was stirred at room temperature for 10 min. The mixture was diluted with toluene (5 mL) and concentrated in vacuo. The residue was diluted with EtOAc, washed with 5% Na 2 CO 3 and brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by column chromatography (NH silica gel, eluted with 0-30% MeOH in EtOAc) to give the title compound 32b (160 mg, 93%) as a colorless amorphous solid. 
2-(2-(2-(3-(2-((S)-1-((S)-2-((S
N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-(2-(2-(3-(2-((S)-1-((S)-2-cyclohexyl-2-((S)-
2-(methylamino
Methyl 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)acetate (28c).
A mixture of methyl 27c ( 
Methyl 2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)acetate (29c).
To a mixture of 28c (680 mg, 3.06 mmol) in pyridine (12 mL) was added p-TsCl (583 mg, 3.06 mmol) at 0 °C. The mixture was stirred at room temperature for 4 h. After the mixture was concentrated in vacuo, the residue was dissolved in EtOAc, washed with 1M HCl aq., sat. NaHCO 3 aq., and brine, dried over Na 2 SO 4 , and concentrated in vacuo.
The residue was purified by column chromatography (silica gel, eluted with 30-100% EtOAc in hexane) to give the title compound 29c (670 mg, 58%) as a colorless oil. 
Methyl 2-(2-(2-(2-(3-(2-((S)-1-((S)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanam ido)-2-cyclohexylacetyl)pyrrolidin-2-yl)thiazole-4-carbonyl)phenoxy)ethoxy)ethoxy )ethoxy)acetate (30c).
A mixture of 29c (320 mg, 0.85 mmol), 18 (509 mg, 0.85 mmol), and K 2 CO 3 (235 mg, 1.70 mmol) in DMSO (3 mL) was stirred at 50 °C overnight. After cooling, the mixture was diluted with EtOAc, washed with 5% NaHCO 3 aq. and brine, dried over Na 2 SO 4 
2-(2-(2-(2-(3-(2-((S)-1-((S)-2-((S)-2-((tert-Butoxycarbonyl)(methyl)amino)propana mido)-2-cyclohexylacetyl)pyrrolidin-2-yl)thiazole-4-carbonyl)phenoxy)ethoxy)etho xy)ethoxy)acetic acid (24c).
To a mixture of 30c (506 mg, 0.63 mmol) in THF (5 mL MS m/z 789.6 (M+H) + .
tert-Butyl
((S)-1-(((S)-2-((S)-2-(4-(3-(2-(2-(2-(2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoy l)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)-2-oxoethoxy)ethoxy)e thoxy)ethoxy)benzoyl)thiazol-2-yl)pyrrolidin-1-yl)-1-cyclohexyl-2-oxoethyl)amino)-
1-oxo-propan-2-yl)(methyl)carbamate (31c).
A mixture of 8 (89 mg, 0.20 mmol), 24c (158 mg, 0.20 mmol), HOBt (38 mg, 0.28 mmol), and EDC (49 µL, 0.28 mmol) in DMF (1.5 mL) was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 5% NaHCO 3 aq. and brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by column chromatography (silica gel, eluted with 0-40% MeOH in EtOAc) to give the title compound 31c (250 mg, quant.) as a yellow solid. 
N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-(2-(2-(2-(3-(2-((S)-1-((S)-2-cyclohexyl-2-(( S)-2-(methylamino)propanamido)acetyl)pyrrolidin-2-yl)thiazole-4-carbonyl)pheno xy)ethoxy)ethoxy)ethoxy)acetyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thia zole-5-carboxamide (32c, SNIPER(ABL)-039).
A mixture of 31c (242 mg, 0.20 mmol) in TFA (4.5 mL) was stirred at room temperature for 10 min. The mixture was diluted with toluene (5 mL) and concentrated in vacuo. The residue was diluted with EtOAc, washed with 5% Na 2 CO 3 and brine, dried over Na 2 SO 4 , and concentrated in vacuo. Methyl 14-(tosyloxy)-3,6,9,12-tetraoxatetradecan-1-oate (29d).
To a mixture of 28d (747 mg, 2.81 mmol) in pyridine (12 mL) was added TsCl (2.14 g, 11.2 mmol) at 0 °C. The mixture was stirred at room temperature for 4 h. After the mixture was concentrated in vacuo, the residue was dissolved in EtOAc, washed with 1M HCl aq., sat. NaHCO 3 aq., and brine, dried over Na 2 SO 4 , and concentrated in vacuo.
The residue was purified by column chromatography (silica gel, eluted with 50-100% 
Methyl
14-(3-(2-((S)-1-((S)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-2-
cyclohexylacetyl)pyrrolidin-2-yl)thiazole-4-carbonyl)phenoxy)-3,6,9,12-tetraoxatet
radecan-1-oate (30d).
A mixture of 29d (300 mg, 0.71 mmol), 18 (427 mg, 0.71 mmol), and K 2 CO 3 (148 mg, 1.07 mmol) in dry DMF (3 mL) was stirred at 50 °C for 2 days. After cooling, the mixture was diluted with EtOAc, washed with 5% NaHCO 3 aq. and brine, dried over 
14-(3-(2-((S)-1-((S)-2-((S)-2-((tert-Butoxycarbonyl)(methyl)amino)propanamido)-2-cyclohexylacetyl)pyrrolidin-2-yl)thiazole-4-carbonyl)phenoxy)-3,6,9,12-tetraoxatet radecan-1-oic acid (24d).
To a mixture of 30d (376 mg, 0.44 mmol) and in THF (3.5 mL)-MeOH (3.5 mL)-water 
tert-Butyl
((S)-1-(((S)-2-((S)-2-(4-
tert-Butyl 4-(4-(ethoxycarbonyl)benzyl)piperazine-1-carboxylate (34).
A mixture of ethyl 4-(chloromethyl)benzoate (33) 
4-((4-(tert-Butoxycarbonyl)piperazin-1-yl)methyl)benzoic acid (35).
A mixture of 34 (1.65 g, 4.74 mmol) and 1M NaOH aq. (7.0 mL, 7.00 mmol) in EtOH (7 mL)-THF (14 mL) was stirred at room temperature overnight. 
N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(piperazin-1-ylme thyl)benzamide 4 hydrochloride (38).
A mixture of 37 (930 mg, 1.60 mmol) and 2M HCl in methanol (30 mL, 60 mmol) was stirred at room temperature overnight. 
4-((4-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)acetyl)piperazin-1-yl)methyl)-N-(4-me thyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (39).
To a mixture of 38 (313 mg, 0.50 mmol), 9 (163 mg, 0.70 mmol), DIPEA (0.52 mL, 2.99 mmol) in DMF (5 mL) was added HATU (266 mg, 0.70 mmol) at 0 °C. The mixture was stirred at 0 °C for 30 min. The mixture was diluted with EtOAc, washed with 5% Na 2 CO 3 aq. and brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by column chromatography (NH silica gel, eluted with 0-20% 
4-((4-(2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)acetyl)piperazin-1-yl)methyl)-N-(4-m ethyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (40).
To (9H-Fluoren-9-yl)methyl
((14S,17S,18R)-17-hydroxy-14-isobutyl-1-(4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-yl)-1,13,
16-trioxo-19-phenyl-3,6,9-trioxa-12,15-diazanonadecan-18-yl)carbamate (41).
To a mixture of 40 (70 mg, 0.10 mmol) and 12 (67 mg, 0.13 mmol) in DMF (2 mL 
4-((4-((14S,17S,18R)-18-Amino-17-hydroxy-14-isobutyl-13,16-dioxo-19-phenyl-3,6,
9-trioxa-12,15-diazanonadecan-1-oyl)piperazin-1-yl)methyl)-N-(4-methyl-3-((4-(py ridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (42, SNIPER(ABL)-049).
A mixture of 41 (124 mg, 0.10 mmol) and 2M dimethylamine in MeOH (4 mL, 8 mmol) was stirred at room temperature overnight. After the mixture was concentrated in vacuo, the residue was purified by column chromatography (NH silica gel, eluted with 
99.7% (HPLC).
tert-Butyl
((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(((S)-1-(4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimi din-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-yl)-1,13-dioxo-15,15-dipheny l-3,6,9-trioxa-12-azapentadecan-14-yl)carbamoyl)pyrrolidin-1-yl)-2-oxoethyl)amin o)-1-oxopropan-2-yl)(methyl)carbamate (43).
To a mixture of 40 (70 mg, 0.10 mmol) and 15 (84 mg, 0.13 mmol) in DMF (3 mL)
were added HATU (56 mg, 0.15 mmol) and DIPEA (26 µL, 0.15 mmol) at 0 °C. The mixture was stirred at 0 °C for 30 min. The mixture was diluted with EtOAc, washed with 5% Na 2 CO 3 aq. and brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by column chromatography (NH silica gel, eluted with 0-40% 
(S)-1-((S)-2-Cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)-N-((S)-1-(4-(4-((4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)pip
erazin-1-yl)-1,13-dioxo-15,15-diphenyl-3,6,9-trioxa-12-azapentadecan-14-yl)pyrroli
dine-2-carboxamide (44, SNIPER(ABL)-050).
A mixture of 43 (125 mg, 0.10 mmol) in TFA (4.5 mL) was stirred at room temperature for 10 min. After the mixture was concentrated in vacuo, the residue was dissolved in EtOAc-THF (ca.5:1), washed with 5% Na 2 CO 3 aq. and brine, dried over Na 2 SO 4 
tert-Butyl
((2S)-1-(((1S)-1-cyclohexyl-2-((2S)-2-(4-(3-(2-(2-(2-(2-(4-(4-((4-methyl-3-((4-(pyridi n-3-yl)pyrimidin-2-yl)amino)phenyl)carbamoyl)benzyl)piperazin-1-yl)-2-oxoethox y)ethoxy)ethoxy)ethoxy)benzoyl)-1,3-thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)amin o)-1-oxopropan-2-yl)methylcarbamate (45).
A mixture of 38 (79 mg, 0.13 mmol), 24c (100 mg, 0. 
4-((4-((2-(2-(2-(3-((2-((2S)-1-((2S)-2-Cyclohexyl-2-((N-methyl-L-alanyl)amino)acety l)pyrrolidin-2-yl)-1,3-thiazol-4-yl)carbonyl)phenoxy)ethoxy)ethoxy)ethoxy)acetyl)p iperazin-1-yl)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pheny l)benzamide (46, SNIPER(ABL)-058).
A mixture of 45 (105 mg, 0.08 mmol) in TFA (3 mL) was stirred at room temperature for 10 min. After the mixture was concentrated in vacuo, the residue was dissolved in 
6-Chloro-N-(4-(trifluoromethoxy)phenyl)pyrimidin-4-amine (49).
To a solution of 4,6-dichloropyrimidine (47) 
3-(6-((4-(Trifluoromethoxy)phenyl)amino)pyrimidin-4-yl)benzoic acid (51).
To a solution of 49 (2.0 g, 6.9 mmol), 3-boronobenzoic acid (50) 
tert-Butyl (1-oxo-1-(3-(6-((4-(trifluoromethoxy)phenyl)amino)pyrimidin-4-yl)phenyl)-
5,8,11-trioxa-2-azatridecan-13-yl)carbamate (53).
To a solution of 51 (500 mg, 1.33 mmol), DIPEA (344 mg, 2.66 mmol), and tert-butyl To a solution of 53 (367 mg, 0.56 mmol) in THF (7.3 mL) was added 4M HCl in CPME To a solution of 53 (367 mg, 0.56 mmol) in THF (7.3 mL) was added 4M HCl in CPME 
tert-Butyl
((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(((S
SNIPER(ABL)-015).
To a solution of 56 (403 mg, 0.34 mmol) in THF (7.3 mL) was added 4M HCl in CPME (6.75 mL, 27 mmol) at room temperature. The mixture was stirred at room temperature for 3 h. The mixture was concentrated in vacuo. m), m), m), m), m), m), m), 7.99 (1H, d, J = 7.8 Hz), 8.19 (1H, d, J = 7.8 Hz), 8.53 (1H, s), m), 8.76 (1H, s), 9.95 (1H, s) . MS m/z 1094.8 (M+H) + . Purity 96.5% (HPLC).
N-(2-(2-(2-(2-Hydroxyethoxy)ethoxy)ethoxy)ethyl)-3-(6-((4-(trifluoromethoxy)phen
yl)amino)pyrimidin-4-yl)benzamide (59).
To a solution of 51 (1.1 g, 2.93 mmol), 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethanol (58) 
tert-Butyl
((S)-1-(((S)-1-cyclohexyl-2-oxo-2-((S)-2-(4-
3-(2-Aminothiazolo[5,4-b]pyridin-5-yl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trif luoromethyl)phenyl)benzamide (76).
A mixture of 75 (1.01 g, 1.58 mmol) in TFA (12 mL) was stirred at room temperature for 30 min. After the mixture was concentrated in vacuo, the residue was dissolved in EtOAc washed with 5% Na 2 CO 3 aq. and brine, dried over Na 2 SO 4 
3-(2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)acetamido)thiazolo[5,4-b]pyridin-5-yl)-
N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (77).
To a mixture of 76 (270 mg, 0.50 mmol), 9 (140 mg, 0.60 mmol), Et 3 N (0.21 mL, 1.51 mmol), and DMAP (61 mg, 0.50 mmol) in dry DMF (5 mL) was added MNBA (344 mg, 1.00 mmol) at 0 °C. The mixture was stirred at room temperature for 2 h. The mixture was diluted with EtOAc, washed with 5% Na 2 CO 3 aq. and brine, dried over To a mixture of 78 (185 mg, 0.25 mmol) and 12 (161 mg, 0.30 mmol) in dry DMF (4.5 mL) were added HATU (135 mg, 0.36 mmol) and DIPEA (88 µL, 0.50 mmol) at 0 °C.
3-(2-
The mixture was stirred at 0 °C for 10 min. The mixture was diluted with EtOAc, washed with 5% NaHCO 3 aq. and brine, dried over Na 2 SO 4 , and concentrated in vacuo. 
ntadecan-14-yl)-pyrrolidine-2-carboxamide (82, SNIPER(ABL)-047).
A mixture of 81 (187 mg, 0.14 mmol) in TFA (3 mL) was stirred at room temperature for 10 min. After the mixture was concentrated in vacuo, the residue was dissolved in EtOAc, washed with 5% Na 2 CO 3 aq. and brine, dried over Na 2 SO 4 A mixture of 83 (165 mg, 0.13 mmol) in TFA (3 mL) was stirred at room temperature for 10 min. The mixture was diluted with toluene (5 mL) and concentrated in vacuo.
tert-Butyl
((S)-1-(((S)-1-cyclohexyl-2-((S)-2-(4-(3-(2-(2-(2-(2-((5-(3-((4-((4-
3-(2-(2-(2-(2-(2-(3-(2-((S)-1-((S)-2-Cyclohexyl-2-((S
The residue was diluted with EtOAc, washed with 5% Na 2 CO 3 and brine, dried over 
